Electroporation Instrument Market to Surpass US$ 328.53 Mn by 2030

Global Electroporation Instrument Market, by Product Type [Systems and Accessories (Electrodes, Cuvettes, Chambers, Kits, Others)], by Application [Protein Production, Drug Delivery, Biomedical Research, Gene Therapy, Ablation (Oncology, Cardiology, Others), Others), By Mode [In-Vitro/Clinical and In-Vivo], by End user [Biopharmaceutical, Companies, Hospitals, Research & Academic, Institutes, Others], and by Region [North America, Latin America, Europe, Asia Pacific, Middle East, and Africa] is estimated to be valued at US$ 232.19 Mn in 2022 and is expected to reach US$ 328.53 Mn by 2030, exhibiting a CAGR of 4.4% during the forecast period (2022-2030) as highlighted in a new report published by Coherent Market Insights.

 Key trends in market includes increasing of inorganic growth activities such as partnership by various key players which is expected to drive the growth of global electroporation instruments market over the forecast period. For instance, In May 2021, Mirus Bio, an innovator in transfection technologies announced that they are entering into a partnership with Gamma Biosciences, a global life sciences company serving the advanced therapy market. Gamma has agreed to make a controlling investment in Mirus Bio. The transaction will support Mirus’ plans to expand Good Manufacturing Practice (GMP) production and commercialization of its flagship product TransIT VirusGEN for large scale manufacturing of Adeno-associated viruses (AAV) and Lentivirus -based viral vectors for gene therapy, as well as further development and commercialization of the platform for in vivo delivery applications

Global Electroporation Market – COVID-19 Impact

The COVID-19 pandemic had a positive impact on the global electroporation instruments market, owing to recent developments in technologies of administering Deoxyribonucleic acid (DNA)-based vaccines against the COVID-19. For instance, according to a news article published on Institute of Electrical and Electronics Engineer (IEEE) spectrum, on May 26, 2021, Inovio Pharmaceuticals, a Pennsylvania based company, is employing electroporation, a technique in which an electrical pulse applied to the skin temporarily opens channels in cells, allowing the DNA-based vaccine against the COVID-19 to enter the human body. Following a standard vaccine injection, Inovio's electroporation device, which resembles an electric toothbrush, is applied to the skin. A weak electric field pulses into the arm at the press of a button, opening channels into the cells. The tool boosts the effectiveness of DNA vaccines in humans. With a US$ 71 million contract to scale up the production of its electroporation device and an undisclosed amount to finance phase II and III investigations of the company's COVID-19 vaccine, the U.S. Department of Defense (DOD) had supported Inovio's strategy in 2020.. In addition, the Bill and Melinda Gates Foundation contributed US$ 5 million to the company as part of an effort to increase equitable access to COVID-19 vaccines.

Browse 44 Market Data Tables and 38 Figures spread through 205 Pages and in-depth TOC on “Global Electroporation Instruments Market”- Forecast to 2030, Global Electroporation Instruments Market, Global Electroporation Instrument Market, by Product Type [Systems and Accessories (Electrodes, Cuvettes, Chambers, Kits, Others)], by Application [Protein Production, Drug Delivery, Biomedical Research, Gene Therapy, Ablation (Oncology, Cardiology, Others), Others), by Mode [In-vitro/clinical and In-vivo], by End user [Biopharmaceutical, Companies, Hospitals, Research & Academic, Institutes, Others], and by Region [North America, Latin America, Europe, Asia Pacific, Middle East, and Africa]

To know the latest trends and insights prevalent in the global electroporation instruments market, click the link below:

https://www.coherentmarketinsights.com/market-insight/electroporation-instruments-market-4631

Moreover, presence of various social associations, which offer support to the patients with cancer is expected to drive the market growth over the forecast period. For instance, The Canadian Cancer Society (CCS) is a national, non-profit, community-based organization that is dedicated to eradicating cancer and improving the quality of life of people living with cancer.

Key Takeaways of the Global Electroporation instrument Market:

• Global electroporation instruments market is expected to exhibit a CAGR of 4.4% during the forecast period owing to key players operating in the electroporation instruments market adopting various strategies such as licensing agreement to fuel growth opportunities in the forecast period. For instance, on June 2020, Immunomic Therapeutics Inc., a privately held clinical-stage biotechnology company, entered into a license agreement with Ichor Medical Systems, a privately held biotechnology company based in California, U.S., to use Electroporation (EP) Delivery Technology in the Phase I study of ITI-1001, a DNA vaccine therapy. When administered to patients with newly diagnosed Glioblastoma, or GBM, Ichor's TriGrid Electroporation technology will help in increasing the cellular uptake of ITI-1001, which is in development by Immunomic Therapeutics
• Among the product type, Accessories segment is estimated to account for the largest market share in 2022 and is expected to retain its dominance during the forecast period. The introduction of technologically advanced electroporation systems by key players is anticipated to drive the segment growth. The presence of key players with significant product offerings for electroporation accessories is anticipated to drive the segment growth. For instance, Bio-Rad Laboratories, Inc., Harvard Bioscience, Inc., Mirus Bio LLC, etc. are the key players offering accessories for electroporation system. Moreover, low cost and frequent use of accessories are expected to be responsible for the segment growth in the near future
• Among the Distribution Channel, Biopharmaceutical Companies segment is estimated to account for the largest market share in 2022 and is expected to retain its dominance during the forecast period. Electroporation is an emerging technique in biotechnological application. This in turn is expected to create lucrative opportunity for the segment growth. Moreover, growth of biopharmaceutical industry due to investments by key players, growing focus on research and development activities, efficacy, and safety of biopharmaceutical products, and increase in the success rate of pipeline products that leads increasing number of product launches are likely to drive the segment growth.
• Major players operating in the global electroporation instruments market are Bio-Rad Laboratories, Inc, Thermo Fisher Scientific Inc., BTX ( a division of Harvard Bioscience), Celetrix, LLC., Gamma Biosciences, Merck KgaA, Eppendorf SE, MaxCyte, Inc. BEX CO.,LTD., Lonza, Altogen Biosystems, Ala Scientific Instruments, Inc., BioEra Life Sciences Pvt. Ltd., and Ichor Medical Systems